> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novo Nordisk Recalls Insulin Product Samples
- URL: https://www.fdaweb.com/novo-nordisk-recalls-insulin-product-samples/
- Published: 2021-05-11T12:00:00.000Z
- Updated: 2026-09-14T16:58:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149295

Novo Nordisk has recalled 1,468 product samples for Levemir (insulin detemir), Tresiba (insulin degludec), Fiasp (insulin aspart), Novolog (insulin aspart) and Xultophy (insulin degludec and liraglutide injection) because they were stored at temperatures below storage requirements. “If product samples are exposed to temperatures below 32°F, it could cause a lack of efficacy and damage to the cartridge and pen-injectors,” a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novo-nordisk-issues-voluntary-nationwide-recall-levemirr-tresibar-fiaspr-novologr-and-xultophyr?ref=fdaweb.com) says. “If product from an improperly stored vial, cartridge or pen-injector is used, there is a risk that you might not receive the right amount of medicine as intended which may lead to hyperglycemia or hypoglycemia resulting in adverse health consequences ranging from limited to life-threatening.”